Ajooni Biotech Limited — Interim / Quarterly Report 2021

Aug 2, 2021

ONI BIOTECH LIMITE

Regd. Office: D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: www.ajoonibiotech.com E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162

Date: 02/08/2021

To. National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Dear Sir / Madam,

Subject: Outcome of the Board Meeting held on August 02, 2021, Monday, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Monday, August 02, 2021 at 11.30 a.m concluded at 01.40 p.m. Following transactions were considered and approved:

• 1. Un-Audited Financial Results for the quarter ended on 30th June 2021.
• 1. The Board has considered and approved the offer and issue of fully paid-up equity shares of the Company, on a rights issue to existing eligible equity shareholders of the Company as at the record date for an amount not exceeding Rs. 30.00 Crore, in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the "Rights Issue").

For the purposes of giving effect to the Rights Issue, the Board has constituted and authorized the Right Issue Committee to decide the terms and conditions of the Rights Issue, including the instrument, issue price, rights entitlement ratio, record date, timing of the Rights Issue and other related matters.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You, Yours Truly. For Ajooni Biotech Limited MOHAL¹ Jasjot Singh Managing Director DIN: 01937631

ONI BIOTECH LIMITEI

Regd. Office: D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: www.ajoonibiotech.com E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162

To, National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Date: 02/08/2021

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-audited Financial Results for the quarter ended 30th June, 2021.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 02/08/2021 at the Registered Office of the company have considered and approved the Audited Financial Statements for the quarter ended 30th June, 2021. In this regards, we are enclosing herewith:

• 1. Un-Audited Financial Results for the quarter ended on 30th June 2021.
• 1. Limited Review Report from the auditor for the quarter ended on 30th June 2021.

You are requested to kindly take the same on record.

Thanking You, Yours Truly, For Ajooni Biotech Limited Jasjot Singh Managing Director DIN: 01937631

		Year Ended (Audited)	11.00.2021 Period Ended (Unaudited)	30.06.2020		5103.88 983.16	1.72 0.51	983.67	5,105.60	4335.59 815.32	$-34.32$ (4.03)	114.78 32.05	58.40 10.44	57.75 15.50		522.98 70.61	5,055.18 939.89	50.42 43.78		50.42 43.78		15.03 $\tilde{\mathbf{e}}$ $\ddot{5}$	1.91 $\circ$		37.30 30.18		(181)	(181)	(144.03) 30.18	1,000.55 840.50	564.51 748.60
			Period Ended (UnAudited)	30.06.2021		1,584.62	0.92	1,585.54		1,342.82	(1.49)	38.10	13.30	18.93		133.08	1,544.74	40.80		40.80		10.50	1.05		31.35				31.35	1,000.55	596.69
		Quarter Ended	30.06.2020			983.16	0.51	983.67		815.32	(4.03)	32.05	10.44	15.50		70.61	939.89	43.78		43.78		13.60			30.18		$\bullet$		30.18	840.50	748.60
			31.03.2021			618.80 -	0.52	1,619.32		1,395.36	(22.74)	29.65	15.12	14.44		182.59	,614.42 $\overline{\phantom{0}}$	4.90		4.90		1.43	0.95		4.42		(45)	(45)	(40.83)	1,000.55	564.51
CIN : LB5190PB2010PLC040162		网络城市	30.06.2021			84.62 $\ddot{5}$	0.92	1,585.54		1,342.82	(1.49)	38.10	13.30	18.93		33.08	1,544.74	40.80		40.80		10.50	1.05		31.35		$\mathfrak b$	$\,$	31.35	1,000.55	596.69
ä	STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 50TH JUNE 2021 (In Lakhs)	PARTICULARS			Income	Revenue from operations	Other income	Total income from operations	Expenses	Cost of Material Consumed	Change In Inventories	Employee benefit expenses	Finance costs	Depreciation and amortization expenses	Payment to NSE	Other expenses	Total expenses	Profit/(Loss) before exceptional items and tax E	IV Exceptional items	Profit/(Loss) before tax	Tax expenses	$a)$ Current tax	b) Deferred tax	b) Mar Credit	VII Net Profit/(Loss) for the period/year	VIII Other comprehensive income (net of tax)	Items that will not be reclassified to profit or loss:	Total other comprehensive income	Total comprehensive income for the period/year (VIJ+VIII)	Paid-up equity share capital (face value of the share shall be indicated)	XI Other equity (excluding revaluation reserve)	XII EPS in Rs. (Face Value of Rs.10/- each)*

	. כ	יטוני n na	0.36	. 31	0.36	0.37
	3		1.36	ני ֧֧֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֚֓֡֡	0.36	0.37
an 39 of the SBBI (LODR) Reminitions. 2015 as amonded and house house relies as second to posed of Prisoners of the second .de above results are as
$\sim$ $\sim$ $\sim$ $\sim$ $\sim$

ave been taken on record by Board of Directors at its meeting held on 02.08.2021 after being reviewed by the Audit Committee.

1. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.

2. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

$\overline{L}$ For Ajoon Engineer Limited Managing Director
DIN:
01937631 Q₂ Jasjot Singh

Date: 02/08/2021

Place: Mohali

AJOONI BIOTECH LIMITED

CIN: L85190PB2010PLC040162

Statement of Assets and Liabilities For the Year ended on 30th june 2021

				in Rs.
	PARTICULARS		30TH JUNE 2021	31ST MARCH 2021
	I. ASSETS
$\left( \underline{1} \right)$	Non - Current Assets
	a) Property, Plant and Equipment		51,705,299	51,617,081
	b) Financial Assets
	(1) Non-Current Investments		11,316,761	11,482,856
	(2) Advances
	c) Deffered Tax Asset		1,570,029	1,465,029
	d) Other Non Current Assets		1,055,272	1,407,030
(2)	Current Assets
	a) Inventories		53,504,349	53,762,090
	b) Financial Assets
	(1) Cash & Cash Equivalent		17,165,795	2,440,976
	(2) Short Term Loans and advances		19,912,284	19,882,931
	(3) Trade Receivables		137,270,404	137,117,389
	c) Other Current Asset		1,087,547	1,087,547
		TOTAL Rs.	294,587,741	280,262,930
	II EQUITY AND LIABILITIES
	$(1)$ Equity
	a) Equity Share Capital		100,055,820	100,055,820
	b) Other Equity		59,669,125	56,451,410
(2)	Non-Current Liabilities
	a) Financial Liabilities
	(1) Borrowings		22,766,076
				18,979,313
(3)	Current Liabilities
	a) Financial Liabilties
	(1) Borrowings		54,472,542	48,857,260
	(2) Trade Payables		54,848,078	54,003,957
	b) Other Current Liabilities		1,726,100	411,890
	c) Current tax liabilities (Net)		1,050,000	1,503,280
		TOTAL Rs.	294,587,741	280,262,930
	Date: 02.08.2021		For Ajoom Bjotech Limited
	Place: Mohali
			HOMALI
			Jasjot Singo Managing Director
			DIN: 01937631

Harjeet Parvesh & Company CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. Ajooni Biotech Limited having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30^th June 2021 ("the Statement") attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh& Co. Chartered Accountants

VBI CA-Konia Madan Partner M.No 547759 Date: 02-08-2021 UDIN: 21547759AAAAAN4351